Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The aim of this perspective article is to stimulate radical shifts in thinking and foster further discussion on the effective discovery, development, validation, and qualification process of biological markers derived from all available technical modalities that meet the complex conceptual and pathophysiological challenges across all stages of the complex, nonlinear, dynamic, and chronically progressive sporadic Alzheimer's disease (AD). This perspective evaluates the current state of the science regarding a broad spectrum of hypothesis‐driven and exploratory technologies and “markers” as candidates for all required biomarker functions, in particular, surrogate indicators of adaptive to maladaptive and compensatory to decompensatory, reversible to irreversible brain “systems failure.” We stress the future importance of the systems biology (SB) paradigm (next to the neural network paradigm) for substantial progress in AD research. SB represents an integrated and deeper investigation of interacting biomolecules within cells and organisms. This approach has only recently become feasible as high‐throughput technologies and mass spectrometric analyses of proteins and lipids, together with rigorous bioinformatics, have evolved. Existing high‐content data derived from clinically and experimentally derived neural tissues point to convergent pathophysiological pathways during the course of AD, transcending traditional descriptive studies to reach a more integrated and comprehensive understanding of AD pathophysiology, derived systems biomarkers, and “druggable” system nodes. The discussion is continued on the premise that the lack of integration of advanced biomarker technologies and transfertilization from more mature translational research fields (e.g., oncology, immunology, cardiovascular), which satisfy regulatory requirements for an accurate, sensitive, and well‐validated surrogate marker of specific pathophysiological processes and/or clinical outcomes, is a major rate‐limiting factor for the successful development and approval of effective treatments for AD prevention. We consider the conceptual, scientific, and technical challenges for the discovery‐development‐validation‐qualification process of biomarker tools and analytical algorithms for detection of the earliest pathophysiological processes in asymptomatic individuals at elevated risk during preclinical stages of AD. The most critical need for rapid translation of putative markers into validated (performance) and standardized (harmonized standard operating procedures) biomarker tools that fulfill regulatory requirements (qualify for use in treatment trials: e.g., safety, target engagement, mechanism of action, enrichment, stratification, secondary and primary outcome, surrogate outcome) is the availability of a large‐scale worldwide comprehensive longitudinal database that includes the following cohorts: (a) healthy aging, (b) people at elevated risks (genetic/epigenetic/lifestyle/comorbid conditions), and (c) asymptomatic–preclinical/prodromal–mild cognitive impairment/syndromal mild, moderate, or severe AD. Our proposal, as initial strategic steps for integrating markers into future development of diagnostic and therapy trial technologies, is to work toward: (a) creating the essential research and development infrastructure as an international shared resource, (b) building the organizational structure for managing such a multinational shared resource, and (c) establishing an integrated transsectoral multidisciplinary global network of collaborating investigators to help build and use the shared research resource.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“[7] Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH,”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 3×
“[6] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S,”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Systems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265
Greicius, M. D., Srivastava, G., Reiss, A. L., & Menon, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308627101 · Cited by 3,684 · cited 2×
“Compared with healthy control individuals (HCs), AD patients show decreased resting-state coactivation within the DMN, particularly across the medial parietal cortex and in the hippocampus [34].”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationBuckner, R. L., Sepulcre, J., Talukdar, T., Krienen, F. M., Liu, H., Hedden, T., Andrews-Hanna, J. R., Sperling, R. A., & Johnson, K. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5062-08.2009 · Cited by 2,862
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140 · cited 2×
“[31] Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R,”
BackgroundInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 1×
“[132] Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC,”
BackgroundSelf-citationAβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 1×
“[133] Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J,”
BackgroundRevising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 3×
“The recent revision [2,3] of the longstanding [4] clinical diagnostic criteria, which have defined several stages of disease progression, reflects growing recognition that the underlying neurobiology of Alzheimer’s syndrome starts many years before the appearance of anymeasurable clinical signs or impairments of funct…”
BackgroundSelf-citationProtein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 9×
“For instance, t-tau might be a valuable biomarker for identifying and monitoring a downstream effect on the intensity of neuronal or axonal degeneration [54].”
BackgroundInfluentialSelf-citationSystematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“[140] Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE.”
BackgroundParietal lobe contributions to episodic memory retrieval
Wagner, A. D., Shannon, B. J., Kahn, I., & Buckner, R. L. (2005) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2005.07.001 · Cited by 1,571 · cited 12×
“Clinical pathological investigations and modern in vivo amyloid-PET imaging studies consistently showed that accumulation of fibrillar Ab deposits in the brain follows a specific temporal-spatial pattern, commencing within brain areas of the default mode network (DMN) and connected pathways of the hippocampal formatio…”
BackgroundInfluentialCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 2×
“Remarkably, the combined use of t-tau, p-tau, and Ab1-42 has been constantly reported to have a high predictive value for identifying cases of prodromal AD in patients with MCI [64,65].”
BackgroundSelf-citationInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Reverse engineering of biological complexity
Csete, M. E., & Doyle, J. C. (2002) · Science · doi:10.1126/science.1069981 · Cited by 1,215
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Dynamics of Gray Matter Loss in Alzheimer's Disease
Thompson, P. M., Hayashi, K. M., de Zubicaray, G., Janke, A. L., Rose, S. E., Semple, J., Herman, D., Hong, M. S., Dittmer, S. S., Doddrell, D. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-03-00994.2003 · Cited by 1,132
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 4×
“[117] Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A,”
BackgroundInfluentialSelective changes of resting-state networks in individuals at risk for Alzheimer’s disease
Sorg, C., Riedl, V., Mühlau, M., Calhoun, V. D., Eichele, T., Läer, L., Drzezga, A., Förstl, H., Kurz, A., Zimmer, C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708803104 · Cited by 1,036
Sperling, R. A., LaViolette, P. S., O'Keefe, K., O'Brien, J., Rentz, D. M., Pihlajamaki, M., Marshall, G., Hyman, B. T., Selkoe, D. J., Hedden, T., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.07.003 · Cited by 1,027
Next-generation DNA sequencing techniques
Ansorge, W. J. (2009) · New Biotechnology · doi:10.1016/j.nbt.2008.12.009 · Cited by 993 · cited 2×
“the technology of the year in 2007 [134]—represent original attractive opportunities in the life sciences.”
BackgroundMethodJack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET
Herholz, K., Salmon, E., Perani, D., Baron, J.-C., Holthoff, V., Frölich, L., Schönknecht, P., Ito, K., Mielke, R., & Kalbe, E. (2002) · NeuroImage · doi:10.1006/nimg.2002.1208 · Cited by 832 · cited 2×
“[38] Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Fr€olich L,”
BackgroundBuchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586
Self-citationPlasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease
Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582
Microvascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434 · cited 2×
“[60] Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A,”
BackgroundSelf-citationHe, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200705042 · Cited by 390
Total and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389 · cited 2×
“The majority of studies demonstrated that patients with AD display an evident increase in CSF amounts of t-tau and p-tau [61] and a considerable reduction in Ab1-42 levels [62].”
BackgroundSelf-citationA Systems Level Analysis of Transcriptional Changes in Alzheimer's Disease and Normal Aging
Miller, J. A., Oldham, M. C., & Geschwind, D. H. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4098-07.2008 · Cited by 385
Miller, S. L., Fenstermacher, E., Bates, J., Blacker, D., Sperling, R. A., & Dickerson, B. C. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.124149 · Cited by 241
Riemenschneider, M., Wagenpfeil, S., Vanderstichele, H., Otto, M., Wiltfang, J., Kretzschmar, H., Vanmechelen, E., Förstl, H., & Kurz, A. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001220 · Cited by 238 · cited 2×
“[59] Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M,”
BackgroundElevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease
Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M. E., Buchhave, P., Londos, E., Umek, R. M., Minthon, L., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1102 · Cited by 224
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211
Fluid Biomarkers in Alzheimer Disease
Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208
Zhong, Z., Ewers, M., Teipel, S., Bürger, K., Wallin, A., Blennow, K., He, P., McAllister, C., Hampel, H., & Shen, Y. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.718 · Cited by 206
Self-citationGenome-wide association study of CSF biomarkers Aβ 1-42 , t-tau, and p-tau 181p in the ADNI cohort
Kim, S., Swaminathan, S., Shen, L., Risacher, S. L., Nho, K., Foroud, T., Shaw, L. M., Trojanowski, J. Q., Potkin, S. G., Huentelman, M. J., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318204a397 · Cited by 206
Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study
Koivunen, J., Scheinin, N., Virta, J. R., Aalto, S., Vahlberg, T., Någren, K., Helin, S., Parkkola, R., Viitanen, M., & Rinne, J. O. (2011) · Neurology · doi:10.1212/wnl.0b013e318212015e · Cited by 188 · cited 2×
“[47] Koivunen J, Scheinin N, Virta JR, Aalto S, Vahlberg T, N agren K,”
BackgroundHampel, H., Bürger, K., Pruessner, J. C., Zinkowski, R., DeBernardis, J., Kerkman, D., Leinsinger, G., Evans, A. C., Davies, P., Möller, H.-J., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.5.770 · Cited by 175 · cited 2×
“[57] Hampel H, B€urger K, Pruessner JC, Zinkowski R, DeBernardis J,”
BackgroundSelf-citationShapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
Jack, C. R., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., Kantarci, K., Bernstein, M. A., Senjem, M. L., Gunter, J. L., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3405 · Cited by 145
Ewers, M., Zhong, Z., Bürger, K., Wallin, A., Blennow, K., Teipel, S. J., Shen, Y., & Hampel, H. (2008) · Brain · doi:10.1093/brain/awn034 · Cited by 119
Self-citationJiang, H., Hampel, H., Prvulovic, D., Wallin, A., Blennow, K., Li, R., & Shen, Y. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-69 · Cited by 99
Self-citationHashimoto, M., Bogdanovic, N., Volkmann, I., Aoki, M., Winblad, B., & Tjernberg, L. O. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0661-6 · Cited by 69
Inflammatory Proteins in Plasma and the Risk of Dementia: The Rotterdam Study
Engelhart, M. J., Geerlings, M. I., Meijer, J., Kiliaan, A., Ruitenberg, A., van Swieten, J. C., Stijnen, T., Hofman, A., Witteman, J. C. M., & Breteler, M. M. B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.668 · Cited by 10 · cited 3×
“[110] Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van”
BackgroundInfluential
Research works printed but not linked: 109
- 10.1016/j.pneurobio.2011.09.004 · DOI
- 10.1016/S1474-4422(07)70178-3 · DOI · Paper page
- 10.1212/WNL.34.7.939 · DOI · Paper page
- 10.1016/j.jalz.2011.03.005 · DOI · Paper page
- 10.1186/1750-1326-4-19 · DOI · Paper page
- 10.1016/j.pneurobio.2011.08.014 · DOI
- 10.1007/BF03256398 · DOI
- Thomas L, 2007, Labor und diagnose
- 10.1007/s12603-009-0036-7 · DOI
- 10.1038/nrd3115 · DOI · Paper page
- 10.1038/nrd1130 · DOI · Paper page
- 10.1067/mcp.2001.113989 · DOI · Paper page
- 10.1111/j.1755-5949.2009.00104.x · DOI · Paper page
- 10.1016/j.pneurobio.2011.07.004 · DOI · Paper page
- 10.1016/j.pneurobio.2011.07.008 · DOI
- Bertram L, 2011, The role of genetics for biomarker development in neurodegeneration, Prog Neurobiol, 95, 501, 10.1016/j.pneurobio.2011.09.011 · DOI
- 10.1016/j.pneurobio.2011.11.008 · DOI · Paper page
- 10.1523/JNEUROSCI.4521-10.2010 · DOI · Paper page
- 10.1002/ana.22365 · DOI · Paper page
- 10.1002/ana.20009 · DOI · Paper page
- 10.1016/j.biopsych.2010.05.013 · DOI · Paper page
- Hampel H. Amyloid‐β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms. J Alzheimers Dis (in press).
- 10.1016/j.neurobiolaging.2010.04.013 · DOI · Paper page
- 10.1093/brain/awl051 · DOI · Paper page
- 10.1148/radiol.10091402 · DOI · Paper page
- 10.1016/j.tins.2011.05.005 · DOI · Paper page
- 10.1212/WNL.0b013e3182563bbe · DOI · Paper page
- 10.1196/annals.1427.007 · DOI · Paper page
- 10.1212/01.WNL.0000147469.18313.3B · DOI · Paper page
- 10.1212/WNL.0b013e3181b23564 · DOI · Paper page
- 10.1212/WNL.0b013e31820af94e · DOI · Paper page
- 10.1016/j.pneurobio.2011.11.009 · DOI
- 10.1007/s12603-012-0044-x · DOI · Paper page
- 10.1007/s12603-012-0021-4 · DOI
- 10.1016/j.jalz.2007.08.006 · DOI · Paper page
- 10.1016/S0304-3940(00)01697-9 · DOI · Paper page
- 10.1016/j.expneurol.2009.09.024 · DOI · Paper page
- 10.1602/neurorx.1.2.213 · DOI · Paper page
- 10.1016/j.jalz.2011.09.172 · DOI · Paper page
- 10.1001/archneurol.2011.183 · DOI · Paper page
- 10.1016/S0014-4886(03)00027-X · DOI
- 10.1038/mp.2008.84 · DOI · Paper page
- 10.1002/ana.20144 · DOI
- 10.1212/01.wnl.0000229925.52203.4c · DOI · Paper page
- 10.1373/clinchem.2006.066720 · DOI · Paper page
- 10.1080/00365510701864610 · DOI · Paper page
- 10.1523/JNEUROSCI.3916-08.2008 · DOI · Paper page
- 10.3233/JAD-2012-111361 · DOI · Paper page
- CLMasters DJSelkoe.Biochemistry of amyloid β‐protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med(in press).
- 10.1038/nm.2221 · DOI
- 10.1016/j.molmed.2006.10.002 · DOI
- 10.1523/JNEUROSCI.4580-03.2004 · DOI · Paper page
- 10.3233/JAD-2010-1253 · DOI · Paper page
- 10.1016/S0006-8993(99)01146-4 · DOI
- 10.1016/S0006-8993(97)01355-3 · DOI
- 10.1371/journal.pone.0016032 · DOI · Paper page
- 10.1371/journal.pone.0018850 · DOI · Paper page
- 10.1002/ana.22448 · DOI · Paper page
- 10.1212/WNL.0b013e318248e568 · DOI · Paper page
- 10.1007/s00702-003-0065-z · DOI
- 10.1038/mp.2008.96 · DOI · Paper page
- 10.1602/neurorx.1.2.226 · DOI · Paper page
- 10.1038/nm1635 · DOI · Paper page
- 10.3233/JAD-2011-111421 · DOI · Paper page
- 10.1001/archneurol.2008.565 · DOI · Paper page
- 10.1212/WNL.57.12.2243 · DOI
- 10.1001/archneur.59.1.71 · DOI · Paper page
- 10.1016/S0197-4580(01)00340-2 · DOI · Paper page
- 10.1001/archneur.59.6.972 · DOI · Paper page
- 10.1002/ana.10272 · DOI · Paper page
- 10.1038/nature01325 · DOI · Paper page
- 10.1001/archneurol.2010.215 · DOI · Paper page
- 10.1007/978-3-0348-8350-4_6 · DOI
- 10.1007/s00406-004-0558-2 · DOI
- 10.1016/S0304-3940(97)00379-0 · DOI
- 10.1016/S0006-8993(97)01355-3 · DOI
- 10.1007/s00406-003-0405-x · DOI
- 10.1016/j.biopsych.2009.01.032 · DOI
- 10.1001/archneurol.2008.530 · DOI · Paper page
- 10.1093/brain/awl279 · DOI · Paper page
- 10.1371/journal.pone.0028527 · DOI · Paper page
- 10.1586/14789450.4.2.227 · DOI · Paper page
- 10.1371/journal.pone.0031501 · DOI · Paper page
- 10.1016/j.tins.2008.10.003 · DOI
- 10.1038/35015709 · DOI · Paper page
- 10.1038/nature01510 · DOI · Paper page
- 10.1016/j.semcancer.2006.03.005 · DOI · Paper page
- Check‐Hayden E, 2008, International genome project launched, Nature, 541, 378, 10.1038/451378b · DOI
- 10.1126/science.319.5862.395 · DOI
- Gottesman I, 1972, Schizophrenia and genetics: a twin study vantage point
- 10.1007/s00406-007-1006-x · DOI
- 10.1586/erm.09.42 · DOI
- 10.1586/erm.10.48 · DOI · Paper page
- 10.1016/j.pneurobio.2010.11.005 · DOI
- 10.1038/nrd2006 · DOI · Paper page
- Oliver KG, 1998, Multiplexed analysis of human cytokines by use of the FlowMetrix system, Clin Chem, 44, 2057, 10.1093/clinchem/44.9.2057 · DOI · Paper page
- 10.1373/clinchem.2004.047084 · DOI · Paper page
- 10.1021/pr050080b · DOI · Paper page
- 10.1186/alzrt49 · DOI · Paper page
- 10.1016/j.biopsych.2010.09.020 · DOI
- 10.1016/S1474-4422(10)70030-2 · DOI
- 10.1038/nature04209 · DOI · Paper page
- 10.18632/aging.100413 · DOI · Paper page
- 10.1002/ana.21634 · DOI
- 10.2741/2677 · DOI
- 10.1002/mas.20338 · DOI
- 10.1007/s00401-011-0808-0 · DOI · Paper page
- ASKesselheim JKarlawish.Biomarkers unbound — the Supreme Court's ruling on diagnostic‐test patents [published online ahead of print May 23 2012]. N Engl Jdoi:10.1056/NEJMp1204164. · doi:10.1056/nejmp1204164
- Hampel H, 2011, Special Issue. Biological markers for neurodegenerative diseases, Prog Neurobiol, 95, 491
Cited by
Deep Learning for Health Informatics
Ravì, D., Wong, C., Deligianni, F., Berthelot, M., Andreu-Perez, J., Lo, B., & Yang, G.-Z. (2017) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2016.2636665 · Cited by 2,000
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citationThe Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857
“Therefore, the risk attributable to specific factors remains unclear, although the recent development of biomarkers for in vivo AD diagnosis (Hampel et al., 2012) promises to alleviate this problem.”
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
Metadata
- Authors
- Hampel, H., Lista, S., & Khachaturian, Z. S.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2012-07
- Volume
- 8
- Issue
- 4
- Pages
- 312-336
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2058267476
- Cited by
- 135
- References
- 53
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.